22062-54-0

Usage

Uses

Used in Organic Synthesis:
5-Fluoro-2-methylbenzyl Alcohol is used as a chemical intermediate in the synthesis of various organic compounds. Its unique structure, which includes a fluorine atom and a methyl group attached to a benzyl alcohol backbone, makes it a valuable building block for the creation of complex molecules in the field of organic chemistry.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Fluoro-2-methylbenzyl Alcohol may be utilized as a starting material for the development of new drugs. Its structural features can be exploited to design molecules with specific biological activities, potentially leading to the discovery of novel therapeutic agents.
Used in Chemical Research:
5-Fluoro-2-methylbenzyl Alcohol is also used as a research tool in academic and industrial laboratories. It can serve as a model compound for studying the effects of fluorination and alkylation on the properties and reactivity of benzyl alcohols, contributing to the broader understanding of organic chemistry principles.
Used in Material Science:
The unique structural features of 5-Fluoro-2-methylbenzyl Alcohol may also find applications in material science, where it could be used to develop new materials with tailored properties. For example, its incorporation into polymers or other materials could result in materials with improved thermal stability, chemical resistance, or other desirable characteristics.

InChI:InChI=1/C8H9FO/c1-6-2-3-8(9)4-7(6)5-10/h2-4,10H,5H2,1H3

Upstream product

• 22062-53-9 5-fluoro-2-methylbenzaldehyde 
• 13194-67-7 4-fluoro-2-iodotoluene 

Downstream Products

• 22062-55-1 2-(chloromethyl)-4-fluoro-1-methylbenzene 
• 261951-71-7 2-(bromomethyl)-4-fluoro-1-methylbenzene 
• 1338466-63-9 C₁₄H₁₀FNS 
• 19451-45-7 2,2'-Dimethyl-5,5'-difluor-trans-stilben 

Relevant academic research and scientific papers

Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor

The sphingomyelin synthase 2 (SMS2) is a potential target for pharmacological intervention in atherosclerosis. However, so far, few selective SMS2 inhibitors and their pharmacological activities were reported. In this study, a class of 2-benzyloxybenzamides were discovered as novel SMS2 inhibitors through scaffold hopping and structural optimization. Among them, Ly93 as one of the most potent inhibitors exhibited IC50 values of 91 nM and 133.9 μM against purified SMS2 and SMS1 respectively. The selectivity ratio of Ly93 was more than 1400-fold for purified SMS2 over SMS1. The in vitro studies indicated that Ly93 not only dose-dependently diminished apoB secretion from Huh7 cells, but also significantly reduced the SMS activity and increased cholesterol efflux from macrophages. Meanwhile, Ly93 inhibited the secretion of LPS-mediated pro-inflammatory cytokine and chemokine in macrophages. The pharmacokinetic profiles of Ly93 performed on C57BL/6J mice demonstrated that Ly93 was orally efficacious. As a potent selective SMS2 inhibitor, Ly93 significantly decreased the plasma SM levels of C57BL/6J mice. Furthermore, Ly93 was capable of dose-dependently attenuating the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice treated with Ly93. In conclusion, we discovered a novel selective SMS2 inhibitor Ly93 and demonstrated its anti-atherosclerotic activities in vivo. The preliminary molecular mechanism-of-action studies revealed its function in lipid homeostasis and inflammation process, which indicated that the selective inhibition of SMS2 would be a promising treatment for atherosclerosis.